Literature DB >> 21963909

Angiotensin IV protects against angiotensin II-induced cardiac injury via AT4 receptor.

Hui Yang1, Xiang-Jun Zeng, Hong-Xia Wang, Li-Ke Zhang, Xiao-Li Dong, Shubin Guo, Jie Du, Hui-Hua Li, Chao-Shu Tang.   

Abstract

Angiotensin II (Ang II) is an important regulator of cardiac function and injury in hypertension. The novel Ang IV peptide/AT4 receptor system has been implicated in several physiological functions and has some effects opposite to those of Ang II. However, little is known about the role of this system in Ang II-induced cardiac injury. Here we studied the effect of Ang IV on Ang II-induced cardiac dysfunction and injury using isolated rat hearts, neonatal cardiomyocytes and cardiac fibroblasts. We found that Ang IV significantly improved Ang II-induced cardiac dysfunction and injury in the isolated heart in response to ischemia/reperfusion (I/R). Moreover, Ang IV inhibited Ang II-induced cardiac cell apoptosis, cardiomyocyte hypertrophy, and proliferation and collagen synthesis of cardiac fibroblasts; these effects were mediated through the AT4 receptor as confirmed by siRNA knockdown. These findings suggest that Ang IV may have a protective effect on Ang II-induced cardiac injury and dysfunction and may be a novel therapeutic target for hypertensive heart disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963909     DOI: 10.1016/j.peptides.2011.09.015

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Angiotensin II and angiotensin 1-7: which is their role in atrial fibrillation?

Authors:  Annamaria Mascolo; Konrad Urbanek; Antonella De Angelis; Maurizio Sessa; Cristina Scavone; Liberato Berrino; Giuseppe Massimo Claudio Rosano; Annalisa Capuano; Francesco Rossi
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

2.  The RGS2 (-391, C>G) genetic variation correlates to antihypertensive drug responses in Chinese patients with essential hypertension.

Authors:  Fazhong He; Jianquan Luo; Zhitao Zhang; Zhiying Luo; Lan Fan; Yijing He; Jiagen Wen; Dingilang Zhu; Jinping Gao; Yan Wang; Yuesheng Qian; Honghao Zhou; Xiaoping Chen; Wei Zhang
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

3.  Inhibition of Angiotensin-II Production Increases Susceptibility to Acute Ischemia/Reperfusion Arrhythmia.

Authors:  Eylem Taskin; Kadir Ali Tuncer; Celal Guven; Salih Tunc Kaya; Nurcan Dursun
Journal:  Med Sci Monit       Date:  2016-11-27

4.  Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.

Authors:  Éva Larouche-Lebel; Kerry A Loughran; Mark A Oyama; Phil F Solter; Danielle S Laughlin; Melissa D Sánchez; Charles-Antoine Assenmacher; Philip R Fox; Ryan C Fries
Journal:  J Vet Intern Med       Date:  2019-06-28       Impact factor: 3.333

5.  Effect of berberine on PPARα-NO signalling pathway in vascular smooth muscle cell proliferation induced by angiotensin IV.

Authors:  Hongmei Qiu; Yang Wu; Quanhua Wang; Changqing Liu; Lai Xue; Hong Wang; Qin Wu; Qingsong Jiang
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

6.  Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis.

Authors:  Meng Zhang; Wenhai Sui; Yanqiu Xing; Jing Cheng; Cheng Cheng; Fei Xue; Jie Zhang; Xiaohong Wang; Cheng Zhang; Panpan Hao; Yun Zhang
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.